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Summary
Objective: To compare the pharmaceutical quality of 
Xenical (chemically produced orlistat) with nine gener-
ic products, each produced by fermentation processes. 
Methods: Xenical 120 mg capsules (Roche, Basel, Swit-
zerland) were used as reference material. Generic prod-
ucts were from India, Malaysia, Argentina, Philippines, 
Uruguay, and Taiwan. Colour, melting temperature, 
crystalline form, particle size, capsule fill mass, active 
pharmaceutical ingredient content, amount of impuri-
ties, and dissolution were compared. Standard physi-
cal and chemical laboratory tests were those developed 
by Roche for Xenical. Results: All nine generic products 
failed the Xenical specifications in four or more tests, 
and two generic products failed in seven tests. A fail-
ure common to all generic products was the amount of 
impurities present, mostly due to different by-products, 
including side-chain homologues not present in Xeni-
cal. Some impurities were unidentified. Two generic 
products tested failed the dissolution test, one product 
formed a capsule-shaped agglomerate on storage and 
resulted in poor (≤15%) dissolution. Six generic products 
were powder formulations. Conclusions: All tested ge-
neric orlistat products were pharmaceutically inferior to 
Xenical. The high levels of impurities in generic orlistat 
products are a major safety and tolerability concern.
Introduction
Orlistat (N-formyl-L-leucine (S)-1-[[(2S,3S)-3-hexyl-4-oxo-
oxetan-2-yl]methyl]dodecyl ester) (fig. 1) is a potent irrevers-
ible inhibitor of gastrointestinal lipases that hydrolyse tri-
acylglycerols in the gastrointestinal tract to free fatty acids 
and monoacylglycerols [1, 2]. This inhibition prevents absorp-
tion of up to one third of all dietary fat, [3] and therefore can 
promote weight loss, maintain lost weight, and prevent weight 
regain in obese patients [4]. The relationship between orlistat 
daily dose and fecal fat excretion is determined by gastro-
intestinal lipase inhibition [3]. The dose-response curve dem-
onstrates a steep portion for doses of up to approximately 
400 mg daily. The orlistat daily dose that produces 50% of the 
maximum effect is approximately 100 mg/day.
Orlistat is patented and chemically synthesised using stere-
ospecific methods which result in ≥99.5% pure product. It is 
manufactured and marketed as 120 mg capsules under the 
brand name Xenical by F. Hoffmann-La Roche Ltd (Roche, 
Basel, Switzerland) since its launch in 1998. Xenical has 
proven to be an invaluable drug in the long-term treatment of 
obese and overweight patients. As of July 2009, more than 
35 million patients had received Xenical. During research and 
development, Roche also evaluated a less expensive fermen-
tation process to produce orlistat using the microorganism 
Streptomyces toxytricini. However, chemical analyses revealed 
a considerable range of impurities in the final product, and 
this process was abandoned. 
Orlistat is polymorphic, existing in distinct crystalline 
forms A and B. Xenical is polymorph form B. Orlistat is 
highly lipophilic and practically insoluble in water, having no 
pKa value within physiological pH. Orlistat powder is ‘sticky’, 
which has consequences for manufacture and dispensing into 
capsules. Roche has overcome these difficulties in Xenical 
capsule production by using a patented granular ‘pellets’ for-
mulation that includes a disintegrant [5]. Stability tests of 
Xenical carried out by Roche revealed a slow decline in dis-
solution rates over the 3-year shelf life at a storage tempera-
ture of 25 °C and relative humidity of 60%.
Although the Xenical patent has expired in 2009, generic 
orlistat had been manufactured and available for purchase for 
several years in those countries whose national laws do not 
support patent protection. 
The current study compares the pharmaceutical quality of 
Xenical with nine generic products. All products were as-
sessed against Roche standard operating procedures (SOPs) 
that describe the qualitative and quantitative pharmaceutical 
tests for physical and chemical purity of orlistat from both 
chemical and fermentative synthesis processes. The analysis 
processes for chemically synthesised orlistat were accepted by 
regulatory authorities as part of the Xenical registration docu-
mentation. Values of reference were the official Roche speci-
fications for product testing at release or at shelf-life, where 
appropriate.
Material and Methods
Generic Products 
Samples of nine generic orlistat products, all 120 mg capsule preparations, 
were purchased for testing (table 1). 
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Fig. 1. Chemical structure of orlistat.
Table 1. Details of Xenical and generic orlistat products tested
Product Manufacturer Country Batch Manufacture date Expiry date Shelf-life, 
months
Test date
Xenical Roche Pharmaceuticals Switzerland B2637 July 2006 July 2009 36 August 2006
Cobese Ranbaxy India 1941737 
1792387 
1853969
Aug. 2008 
July 2007 
January 2008
June 2010 
May 2009 
December 2009
24 
22 
24
December 2008
Cuvarlix Pharmaniaga Malaysia 8L184 September 2008 September 2010 24 February 2009
Fingras Phoenix Argentina 15026 (1) (1) unknown December 2006
Lesofat InnoGen Pharma Group Philippines 7E149B May 2007 May 2009 24 November 2007
Obelit Intas Pharma India H5018W (1) (1) unknown December 2005
Xeniplus Elea Argentina L8114 (1) (1) unknown December 2006
Xiluet Servimedic Uruguay 01 (1) February 2008 unknown April 2007
Xinplex Craveri Argentina 9661 (1) (1) unknown December 2006
Zerocal Pharmosa/Weidar Chemical  
and Pharmaceutical Co. Ltd
Taiwan 735002 February 2007 February 2009 24 May 2007
(1) = Not stated on packaging.
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Introduction
Orlistat (N-formyl-L-leucine (S)-1-[[(2S,3S)-3-hexyl-4-oxo-
oxetan-2-yl]methyl]dodecyl ester) (fig. 1) is a potent irrevers-
ible inhibitor of gastrointestinal lipases that hydrolyse tri-
acylglycerols in the gastrointestinal tract to free fatty acids 
and monoacylglycerols [1, 2]. This inhibition prevents absorp-
tion of up to one third of all dietary fat, [3] and therefore can 
promote weight loss, maintain lost weight, and prevent weight 
regain in obese patients [4]. The relationship between orlistat 
daily dose and fecal fat excretion is determined by gastro-
intestinal lipase inhibition [3]. The dose-response curve dem-
onstrates a steep portion for doses of up to approximately 
400 mg daily. The orlistat daily dose that produces 50% of the 
maximum effect is approximately 100 mg/day.
Orlistat is patented and chemically synthesised using stere-
ospecific methods which result in ≥99.5% pure product. It is 
manufactured and marketed as 120 mg capsules under the 
brand name Xenical by F. Hoffmann-La Roche Ltd (Roche, 
Basel, Switzerland) since its launch in 1998. Xenical has 
proven to be an invaluable drug in the long-term treatment of 
obese and overweight patients. As of July 2009, more than 
35 million patients had received Xenical. During research and 
development, Roche also evaluated a less expensive fermen-
tation process to produce orlistat using the microorganism 
Streptomyces toxytricini. However, chemical analyses revealed 
a considerable range of impurities in the final product, and 
this process was abandoned. 
Orlistat is polymorphic, existing in distinct crystalline 
forms A and B. Xenical is polymorph form B. Orlistat is 
highly lipophilic and practically insoluble in water, having no 
pKa value within physiological pH. Orlistat powder is ‘sticky’, 
which has consequences for manufacture and dispensing into 
capsules. Roche has overcome these difficulties in Xenical 
capsule production by using a patented granular ‘pellets’ for-
mulation that includes a disintegrant [5]. Stability tests of 
Xenical carried out by Roche revealed a slow decline in dis-
solution rates over the 3-year shelf life at a storage tempera-
ture of 25 °C and relative humidity of 60%.
Although the Xenical patent has expired in 2009, generic 
orlistat had been manufactured and available for purchase for 
several years in those countries whose national laws do not 
support patent protection. 
The current study compares the pharmaceutical quality of 
Xenical with nine generic products. All products were as-
sessed against Roche standard operating procedures (SOPs) 
that describe the qualitative and quantitative pharmaceutical 
tests for physical and chemical purity of orlistat from both 
chemical and fermentative synthesis processes. The analysis 
processes for chemically synthesised orlistat were accepted by 
regulatory authorities as part of the Xenical registration docu-
mentation. Values of reference were the official Roche speci-
fications for product testing at release or at shelf-life, where 
appropriate.
Material and Methods
Generic Products 
Samples of nine generic orlistat products, all 120 mg capsule preparations, 
were purchased for testing (table 1). 
Pharmaceutical Quality Tests 
The tests were colour of capsule contents, identification of the active 
pharmaceutical ingredient (API) and the crystalline form, melting tem-
perature, particle size, dissolution, fill mass of capsules, content of orlistat 
and of impurities. 
Colour of Capsule Contents
Colour was assessed visually according to the standards described in the 
‘Munsell Book of Color’ [6].
Identification of API and Crystalline Form
Infrared spectroscopy was used with a suspension of 5 mg capsule content 
in Nujol/sodium chloride plates. The spectrum was recorded in the range 
of 4,000–650/cm using a Nicolet 20 SXB spectrophotometer and compared 
to the reference spectra of the polymorphic forms A and B of orlistat.
Melting Temperature 
Melting temperature of the capsule content was determined using a Met-
tler DSC-821e DSC module equipped with a Mettler TSO801RO sample 
robot and STARe, TA-8000 evaluation and control system (Mettler To-
ledo, Greifensee, Switzerland). Determinations were made using between 
6.0 and 13.0 mg of capsule content in a 40 ml sealed aluminium crucible 
under a nitrogen atmosphere, across the temperature range 25–60 °C, and 
using a ramp rate of 1 °C/min. Polymorphic form B has a melting point of 
43.6 °C.
Particle Size 
Particle size analysis was performed by laser diffraction, using a Master-
Sizer 2000, (Malvern Instruments, Worcestershire, UK) fitted with a Sci-
rocco 2000 dry powder feeder (Malvern Instruments) operated at 25 ºC 
with a measuring time of 15 s, a feed rate of approximately 60%, and ob-
scuration limits set between 0.1 and 6%. The entire content of one cap-
sule was used per determination; 3, 6, or 9 separate determinations were 
made, and an average was taken. Xenical pellets show a mean particle 
size distribution of D50 = 1,100 μm and D90 = 1,500 μm. The D50 and 
D90 represent the median or 50th percentile and the 90th percentile of 
the particle size distribution, respectively, as measured by volume. 
Dissolution 
Dissolution testing was performed using the Ph. Eur. rotating paddle ap-
paratus in a dissolution medium that was developed especially for orlistat 
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All pharmaceutical quality tests were conducted in GMP-regulated 
Quality Control and Development Laboratories of F. Hoffman La- 
Roche, in Basel, by certified personnel.
Results 
Five generic products did not fully detail dates of manufacture 
and/or expiry (table 1). The age of product when tested was 
unknown for Fingras, Obelit, Xeniplus, and Xinplex. Xiluet 
was tested within 10 months of expiry. The remaining generic 
products were tested between 3 and 6 months of manufacture. 
Where stated, the maximum shelf life claimed for generic 
products was 2 years, i.e. 1 year less than Xenical. 
Colour, Appearance, Crystalline Form, and Melting 
Temperature
All generic products were white or off-white in colour, similar 
to Xenical (table 2). Lesofat, Xiluet, and Xinplex were pel-
leted or granular formulations resembling Xenical; however, 
five of the remaining generic products were powders and the 
contents of the Cuvarlix capsules remained in a single lump 
(fig. 2). Six of the generic products consisted solely of poly-
morphic form A and three products (Xiluet, Fingras, and Xin-
plex) were mixtures of form A and B. Melting temperatures 
were determined for six generic products, and all were similar 
to Xenical. 
Particle Size Distribution 
Xenical exhibited a narrow range particle size distribution 
with a median (D50) of 1,100 μm (fig. 3). Cobese, a typical 
powder formulation, exhibited a wider range of particle sizes 
with bimodal values of 100 and 900 μm. Particle size distribu-
tions of the granular formulations Xiluet, Xinplex, and Leso-
fat were similar to that of Xenical (fig. 4), with a median size 
substance due to its hydrophobicity. The dissolution medium comprised 
an aqueous solution containing 3% of sodium lauryl sulphate, 0.5% of so-
dium chloride, adjusted to pH 6.0 with phosphoric acid; sink conditions 
were achieved because the solubility of orlistat in this medium is approxi-
mately 0.3 g in 100 ml. The rate of dissolution was determined individually 
for six capsules of each generic product, in a vessel with a paddle stirrer at 
75 rpm and containing 900 ml of medium. Aliquots of 10 ml were removed 
after 15, 30, 45 and 60 min. These aliquots were filtered through a 1 mm 
Acrodisc glass fibre filter or 0.2 mm Acrodisc filter (Pall Medical, Milan, 
Italy) and cooled to 20 °C, and 20 ml samples of the resultant clear solution 
were assayed using high performance liquid chromatography (HPLC) and 
spectrophotometry. The specification for Xenical dissolution rate at shelf-
life was a Q-value of 65% after 45 min according to Ph. Eur. 
Fill Mass of Capsules
Twenty capsules were emptied, their contents mixed together weighed 
and the average weight calculated. Xenical specification for fill mass was 
228.2–252.2 mg per capsule.
Content of Orlistat and of Impurities
The content of orlistat and impurities was determined using HPLC. 
Twenty capsules were emptied and their contents mixed together, from 
which 100 mg was dissolved in 70 ml mobile phase, agitated by ultrasound 
for 1 min, then made up to 100 ml before being agitated for a further 
15 min. A portion of the resulting solution was filtered (0.45 μm pore size, 
Millex HV; Millipore, Volketswil, Switzerland) and stored for up to 48 h 
at 4 °C. Samples (20 ml) were then injected onto the HPLC analytical 
 column (150 mm × 3.9 mm Nova Pak C18, 4 mm; Waters, Baden-Dättwil, 
Switzerland), and eluates monitored at 195 nm (Hewlett Packard G1314A 
variable wavelength detector). The mobile phase comprised acetonitrile 
(860 ml), water (140 ml) and 5% phosphoric acid (1 ml). Mobile phases 
were degassed (Hewlett Packard G1322A vacuum degasser) and pumped 
(Hewlett Packard G1311A quat pump) at 1.0 ml/min. 
The specification for content of API was 114.0–126.0 mg (95–105%) 
orlistat per capsule of Xenical. The specification for the limit for all impu-
rities in Xenical was 0.5% and 2.5% at release and at shelf-life, respec-
tively. The shelf-life limits were between 0.2 and 1.2% for five specific 
degradation products. Each other characterised impurity, which included 
precursors, stereoisomers, side-chain homologues, amino acid analogues 
or other degradation products, was limited at 0.3%. The limits were 0.5% 
for all unidentified impurities at shelf-life. 
Table 2. Physical characteristics of Xenical and generic orlistat products, following removal from capsules
Drug product Description Melting  
temperaturea, °C
Polymorphic  
crystalline form 
Average fill 
massb, mg
Average orlistatc 
content, mg
colour appearance
Xenical white / off-white pellets 43.6 B 240.6 118.3
Cobese almost white powder 43.1 A 231.2 113.7
Cuvarlix off-white highly agglomerated powder 44.8 A 243.8 120.1
Fingras off-white powder 42.2 B and A 248.9 116.2
Lesofat off-white pellets 42.1 A 245.8 116.2
Obelit off-white powder NT A 260.6 114.6
Xeniplus off-white powder 42.2 A 252.3 117.8
Xiluet off-white spheroids NT A and B 332.1 116.9
Xinplex off-white irregular balls 41.1 B (some A) 244.7 114.1
Zerocal white powder NT A 184.4 126.4
NT = Not tested.
aSpecification 42–44 °C. 
bSpecification 228.2–252.2 mg. 
cSpecification 114.0–126.0 mg.
Fig. 2. Physical appearance of capsules and 
contents of  Xenical and three generic products.
Fig. 3. Comparison of particle size distribution 
for Xenical and Cobese. 
Fig. 4. Particle size distribution of  Xenical and 
generic orlistat products.
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All pharmaceutical quality tests were conducted in GMP-regulated 
Quality Control and Development Laboratories of F. Hoffman La- 
Roche, in Basel, by certified personnel.
Results 
Five generic products did not fully detail dates of manufacture 
and/or expiry (table 1). The age of product when tested was 
unknown for Fingras, Obelit, Xeniplus, and Xinplex. Xiluet 
was tested within 10 months of expiry. The remaining generic 
products were tested between 3 and 6 months of manufacture. 
Where stated, the maximum shelf life claimed for generic 
products was 2 years, i.e. 1 year less than Xenical. 
Colour, Appearance, Crystalline Form, and Melting 
Temperature
All generic products were white or off-white in colour, similar 
to Xenical (table 2). Lesofat, Xiluet, and Xinplex were pel-
leted or granular formulations resembling Xenical; however, 
five of the remaining generic products were powders and the 
contents of the Cuvarlix capsules remained in a single lump 
(fig. 2). Six of the generic products consisted solely of poly-
morphic form A and three products (Xiluet, Fingras, and Xin-
plex) were mixtures of form A and B. Melting temperatures 
were determined for six generic products, and all were similar 
to Xenical. 
Particle Size Distribution 
Xenical exhibited a narrow range particle size distribution 
with a median (D50) of 1,100 μm (fig. 3). Cobese, a typical 
powder formulation, exhibited a wider range of particle sizes 
with bimodal values of 100 and 900 μm. Particle size distribu-
tions of the granular formulations Xiluet, Xinplex, and Leso-
fat were similar to that of Xenical (fig. 4), with a median size 
Table 2. Physical characteristics of Xenical and generic orlistat products, following removal from capsules
Drug product Description Melting  
temperaturea, °C
Polymorphic  
crystalline form 
Average fill 
massb, mg
Average orlistatc 
content, mg
colour appearance
Xenical white / off-white pellets 43.6 B 240.6 118.3
Cobese almost white powder 43.1 A 231.2 113.7
Cuvarlix off-white highly agglomerated powder 44.8 A 243.8 120.1
Fingras off-white powder 42.2 B and A 248.9 116.2
Lesofat off-white pellets 42.1 A 245.8 116.2
Obelit off-white powder NT A 260.6 114.6
Xeniplus off-white powder 42.2 A 252.3 117.8
Xiluet off-white spheroids NT A and B 332.1 116.9
Xinplex off-white irregular balls 41.1 B (some A) 244.7 114.1
Zerocal white powder NT A 184.4 126.4
NT = Not tested.
aSpecification 42–44 °C. 
bSpecification 228.2–252.2 mg. 
cSpecification 114.0–126.0 mg.
Fig. 2. Physical appearance of capsules and 
contents of  Xenical and three generic products.
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of 1,100 μm. Particle sizes of five ‘powder’ form generics (Fin-
gras, Xeniplus, Cobese, Zerocal, and Obelit) were generally 
much smaller, with median particle size of ≤500 μm. 
Fill Mass and Orlistat Content of Capsules
The average fill mass of five of the nine generic products fell 
within the Roche specification of 228.2–252.2 mg per capsule 
(table 2). Three generic products (Xeniplus, Obelit, and 
Xiluet) exceeded the upper limit by up to 31.7% (Xiluet 
332.1 mg), whereas Zerocal fell below the lower limit by 19% 
(184.4 mg). The average orlistat content requirement of 
114.0–126.0 mg per capsule was met by six generic products, 
whilst Zerocal (126.4 mg) exceeded specification.
Impurities 
All generic products failed to meet the Roche specification 
for the total of all impurities of 0.5% at release, and five 
 generic products failed to meet the specification of 2.5% at 
shelf-life (range 1.2–4.6%), (fig. 5A). The impurities observed 
in the generic products were due to different chemicals, in-
cluding side-chain homologues and amino acid analogues not 
present in Xenical. 
All nine generic products contained side-chain homologues 
(range 0.8–2.4%, fig. 5B). Three generic products (Cuvarlix, 
Xeniplus, and Xinplex) each contained excessive amounts of 
at least four individual side-chain homologues (data not 
shown). 
Six generic products contained higher levels of unidenti-
fied impurities than Xenical. Two generic products, Obelit 
(1.5%) and Xinplex (0.71%), exceeded specification of 0.5% 
(fig. 5C). 
Dissolution Rate 
Five generic products fully satisfied the 65% Q-value shelf-
life specification for dissolution rates (fig. 6). Obelit exhibited 
marked variation in dissolution rates with many values falling 
below the acceptable dissolution rate; Cuvarlix exhibited very 
poor dissolution (≤15%). 
Number of Violations of Roche Specifications
All generic products failed to match Xenical in four or more 
tests, and two generic products failed in seven tests (table 3). 
A failure common to all generic products was the amount of 
impurities present, some of which were unidentified. Two 
 generic products tested failed the dissolution test.
Discussion
Orlistat is polymorphic, existing in two distinct crystalline 
forms with similar physical properties in terms of solubility, 
dissolution rate of the pure substance, and hygroscopicity. 
This explains our findings of similar melting temperatures 
among the generic products tested compared to Xenical.
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Fig. 5. Summary of impurities (%) in Xenical 
and generic orlistat products: A Total organic 
impurity content. B Total side chain homo-
logues. C Unidentified impurities.
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of 1,100 μm. Particle sizes of five ‘powder’ form generics (Fin-
gras, Xeniplus, Cobese, Zerocal, and Obelit) were generally 
much smaller, with median particle size of ≤500 μm. 
Fill Mass and Orlistat Content of Capsules
The average fill mass of five of the nine generic products fell 
within the Roche specification of 228.2–252.2 mg per capsule 
(table 2). Three generic products (Xeniplus, Obelit, and 
Xiluet) exceeded the upper limit by up to 31.7% (Xiluet 
332.1 mg), whereas Zerocal fell below the lower limit by 19% 
(184.4 mg). The average orlistat content requirement of 
114.0–126.0 mg per capsule was met by six generic products, 
whilst Zerocal (126.4 mg) exceeded specification.
Impurities 
All generic products failed to meet the Roche specification 
for the total of all impurities of 0.5% at release, and five 
 generic products failed to meet the specification of 2.5% at 
shelf-life (range 1.2–4.6%), (fig. 5A). The impurities observed 
in the generic products were due to different chemicals, in-
cluding side-chain homologues and amino acid analogues not 
present in Xenical. 
All nine generic products contained side-chain homologues 
(range 0.8–2.4%, fig. 5B). Three generic products (Cuvarlix, 
Xeniplus, and Xinplex) each contained excessive amounts of 
at least four individual side-chain homologues (data not 
shown). 
Six generic products contained higher levels of unidenti-
fied impurities than Xenical. Two generic products, Obelit 
(1.5%) and Xinplex (0.71%), exceeded specification of 0.5% 
(fig. 5C). 
Dissolution Rate 
Five generic products fully satisfied the 65% Q-value shelf-
life specification for dissolution rates (fig. 6). Obelit exhibited 
marked variation in dissolution rates with many values falling 
below the acceptable dissolution rate; Cuvarlix exhibited very 
poor dissolution (≤15%). 
Number of Violations of Roche Specifications
All generic products failed to match Xenical in four or more 
tests, and two generic products failed in seven tests (table 3). 
A failure common to all generic products was the amount of 
impurities present, some of which were unidentified. Two 
 generic products tested failed the dissolution test.
Discussion
Orlistat is polymorphic, existing in two distinct crystalline 
forms with similar physical properties in terms of solubility, 
dissolution rate of the pure substance, and hygroscopicity. 
This explains our findings of similar melting temperatures 
among the generic products tested compared to Xenical.
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should be borne by the generic manufacturers, rather than the 
original patent holder. If a generic product achieves the same 
weight loss for a much lower cost, then it could be argued that 
the pharmaceutical differences, in terms of efficacy, are not 
important.  
For the tested generic products, the spectrum and amount 
of impurities reflect the complex biological processes inher-
ent in fermentation and the increased difficulties in extract-
ing pure product. A more serious finding, however, was the 
relatively large amount of unidentified organic material in 
Obelit and Xinplex, which raises toxicological questions for 
these products. As orlistat formulations may be given to 
 patients over long periods of time, possibly for the rest of 
their lives, the issue of toxicological effects of impurities may 
be serious due to their possible accumulation in these pa-
tients. As with the requirement for efficacy studies, the onus 
should be on generic manufacturers to provide clinical evi-
dence that their products, particularly when less pure than 
the patented product, are not associated with additional 
side-effects.
Conclusions
The pharmaceutical quality of nine generic products was com-
pared with Xenical. The wide spectrum of impurities indicates 
that the generic products were produced using fermentative 
processes. On the basis of the poor dissolution rates and the 
wide spectrum of impurities observed, we must question 
whether the nine generic products tested can be said to repre-
sent pure, safe and consistent alternatives to Xenical.
Disclosure
PWT, IA and INS have provided consultancy services to F. Hoffman 
 La-Roche Ltd. AF is an employee of F. Hoffman La-Roche Ltd.
Previous studies have found some generic products to be 
less uniform in terms of unit fill mass and amount of active 
ingredient and to contain more impurities than the innovator 
product [7–11]. We compared the pharmaceutical quality of 
synthetically produced orlistat (Xenical) with nine generic 
products. The wide spectrum and identity of impurities was 
consistent with these products being produced via fermenta-
tion processes. We could identify two areas of concern: disso-
lution rate and impurity content, with corresponding potential 
consequences on dose delivery and toxicological issues, re-
spectively. Both may also have an impact on efficacy and 
safety, respectively. We did not include the wholesale or retail 
costs of products although this can be a major argument for 
the development and usage of generic products. 
Stability tests of Xenical carried out by Roche revealed a 
slow decline in dissolution rates over a 3-year period at a stor-
age temperature of 25 °C and 60% relative humidity. Al-
though successful dissolution in vitro does not guarantee 
equivalent dissolution in vivo and does not always reflect in 
vivo availability, such tests are required for registration to 
demonstrate batch-to-batch consistency during manufacture. 
The dose-response of orlistat exhibits considerable variability 
among individuals [3], which was attributed to how well orli-
stat mixed with the fat content of a meal [12]. This step might 
be influenced by the dissolution of the product. Suggestively, 
in a clinical comparison of orlistat formulations, a granulated 
formulation tended towards superior efficacy over a pow-
dered formulation in increasing dietary fat excretion [13]. In 
this context, the very low dissolution rate shown by Cuvarlix 
and the large variation in dissolution rates observed with Ob-
elit are causes for clinical concern as they indicate that little 
orlistat might be available and, hence, that the products would 
be expected to have markedly reduced efficacy. Such clinical 
efficacy concerns with generic products can only be addressed 
by controlled clinical studies, designed to meet the same end-
points as in the original study, that is faecal fat excretion and/
or weight loss over time. The cost of conducting such studies 
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